EPO Market Stabilizes, But For How Long?

Amgen hoped it would be turning the page on the regulatory and reimbursement problems that dogged Aranesp and made 2007 a year to forget. But more negative data means another trip to an FDA advisory committee, and this time Wall Street is bracing for the worst.